Document is current
Any future updates will be listed below
-
Authors
Plant, Natalie
Mylonas, Adam
Sengupta, Chandrima
Nguyen, Doan Trang
Silvester, Shona
Pryor, David
Greer, Peter
Lee, Yoo Young
Ramachandran, Prabhakar
Seshadri, Venkatakrishnan
Trada, Yuvnik
Khor, Richard
Wang, Tim
Hardcastle, Nicholas
Keall, Paul
-
Funding
Funding for this research was provided by:
Cancer Institute NSW (2019/TPG2165, 2019/TPG2165, 2019/TPG2165)
National Health and Medical Research Council (APP1194004)
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 17 September 2024
First Online: 8 October 2024
Declarations
:
: The ethical aspects of this research project have been approved by the Metro South Hospital and Health Service Human Research Ethics Committee (Metro South HREC; registration EC00167). Victorian Specific Modules (VSM) for retrospective and prospective recruitment types, required for all Victorian sites, was also approved by Metro South HREC. Public Health Act (PHA) approval was provided by the Director of Health Innovation, Investment and Research Office, Queensland Health for Queensland sites for access to data via waiver of consent. Consenting procedures, including a waiver of the need to consent for retrospectively recruited participants, were approved by the Metro South HREC.
: Not applicable.
: The University of Sydney, Prof Paul Keall, Adam Mylonas and Dr Doan Trang Nguyen are inventors on a filed patent on markerless tracking that is owned by SeeTreat Pty Ltd. Prof Paul Keall and Dr Doan Trang Nguyen are shareholders and directors of SeeTreat.
